Early-stage cell therapy startup March Biosciences has partnered with CTMC. Photo via march.bio

When it came time to name their cell therapy startup, Houston life science innovators simply had to look to their calendar.

“I would argue that March is the best month in Houston,” Sarah Hein tells InnovationMap. “We started talking about putting this company together during COVID, so we were outside a lot. And we actually got together in March.”

That’s why the CEO and her co-founders Max Mamonkin and Malcolm Brenner decided to name their company March Biosciences.

It's a fresh, unstuffy name for a startup that has an innovative take on cancer immunotherapy. Their lead asset is an advanced cellular therapy known as MB-105, an autologous CD5 CAR T cell therapy. For patients with T-cell lymphoma and leukemia who have failed all currently available lines of therapy, the prognosis is understandably extremely poor. But in a phase one study, MB-105 has been proven to safely treat those patients. The phase two study is expected to begin in the first half of 2024.

Hein met Mamonkin at the TMC Accelerator for Cancer Therapeutics (ACT), at which the alumna of Resonant Therapeutics and Courier Therapeutics was an entrepreneur in residence.

“It's a perfect example of the opportunities here in Houston where you can go from bench to bedside, essentially, in the same institution. And Baylor has been particularly good at that because of the Center for Cell and Gene Therapy,” says Hein.

The serial entrepreneur first came to Houston as a PhD student in molecular and cellular biology at Baylor College of Medicine, but during her studies she became excited by the startup ecosystem in her new hometown. After earning her degree, she became a venture fellow at the Mercury Fund. Her experience in both science and business made her an ideal candidate to take March Biosciences to the next level.

In September, the company announced that it formed a strategic alliance with CTMC (Cell Therapy Manufacturing Center), a joint venture between MD Anderson Cancer Center and National Resilience.

“Our unique risk-sharing model allows us to collaborate with organizations like March Biosciences to accelerate the development and manufacture of innovative cell therapies, like MB-105, and bring them into the clinic with a consistent and scalable manufacturing process,” said CTMC’s CEO, Jason Bock in a press release.

The partnership “has allowed us to move really quickly,” Hein says.

That’s because what CTMC does uniquely well is take early stage companies like March Biosciences and advance them to a state that’s ready for manufacturing in a short time, around 18 months, says Hein.

According to Hein, March Biosciences’ success is a testament to Houston and its world-class medical center.

“It’s a great example of the opportunities you see here in Houston, where we have a technology that was developed by brilliant scientists here in Houston and we can pull together the resources that we need to take it to the next level,” Hein says. "Working with partners here in Houston, we have all the pieces and the community rises to the occasion to support you.”

This week's roundup of Houston innovators includes Jason Bock of CTMC, Barbara Burger, and Mario Amaro of Ease. Photos courtesy

3 Houston innovators to know this week

who's who

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from cell therapy to energy transition — recently making headlines in Houston innovation.

Jason Bock, founder and CEO of CTMC

Jason Bock, founder and CEO of the Cell Therapy Manufacturing Center, joins the Houston Innovators Podcast to explain the complicated — yet necessary — process of scaling cell therapies. Photo courtesy

Last year, a project out of MD Anderson spun out to create a new joint venture, CTMC — Cell Therapy Manufacturing Center, with National Resilience, a company that was founded to help advance life-saving therapeutics. The JV is based in the Texas Medical Center and led by CEO Jason Bock, who says the entity's location is critical.

"Houston has a chance to play a role in all aspects of cell therapy," he says, from discovery to the clinical side. "Some really interesting cell therapies that are in development were discovered here in Houston."

Bock shares more on how the impact CTMC is making on cell therapy advancement on the podcast. Read more.

Barbara J. Burger, startup adviser and mentor 

Energy innovation expert, Barbara Burger, shares how she sees the future of energy playing out as a dance between mice — the startups — and elephants — the incumbent corporations. Photo courtesy

The way Barbara Burger sees it, the energy transition depends on a dance between startups, or the mice, and corporates, aka the elephants. In a guest column for InnovationMap, she explains what questions each side needs to address.

"There are lots of questions here and the why is often an iterative journey for both sides," she explains. "It is as much mindset, influence, strategy, champions, and risk tolerance at individual levels as it about technology and economics." Read more.

Mario Amaro, CEO and founder of Ease

Mario Amaro, founder of Ease, was selected for one of Amazon's accelerator programs. Photo courtesy of Amazon

Amazon's AWS Impact Accelerator Latino Founders Cohort named the 20 startups joining its accelerator that will connect Latinx founders to its network of mentors, provide programming, and even dole out funding.

Houston-based Ease, founded by Mario Amaro in 2018, the health care fintech platform allows for medical professionals to start, grow, and manage their private practices with bookkeeping tools and other software infrastructure. So far, the company has worked with more than 300 practices. Read more.

Jason Bock, founder and CEO of the Cell Therapy Manufacturing Center, joins the Houston Innovators Podcast to explain the complicated — yet necessary — process of scaling cell therapies. Photo courtesy

Houston innovator aims to scale cancer-curing cell therapies

HOUSTON INNOVATORS PODCAST EPISODE 185

It's almost unreal what can be done with therapeutics today, especially in the specialty of cell therapy.

"It feels like science fiction," says Jason Bock, founder and CEO of the Cell Therapy Manufacturing Center, or CTMC, a joint venture between National Resilience and MD Anderson Cancer Center.

Cell therapy is essentially personalized medicine, he explains. The process includes taking out a patient’s own immune cells, identifying specifically the T-cells, and engineer them to have them target cancer before expanding them and reintroducing them to the patient.

“The supply chain begins with the patient,” Bock explains on the Houston Innovators Podcast. “If the patient is going to be an integral part of the supply chain, one way to simplify your supply chain is to locate your manufacturing very close to where your patients are.”

That's where CTMC, located in the heart of the Texas Medical Center, comes in. Bock moved to Houston from the East Coast four years to stand up the program at MD Anderson. The founding thesis was to work with faculty members who have interesting ideas for biologics or cell therapies, help them industrialize them, and then bring them into the MD Anderson clinic to evaluate in patients.

Last year, the entity spun out into a joint venture structure with National Resilience, a company that was founded amid the pandemic to build resilience in the nation for complex biologics manufacturing — like vaccines, for instance — in order to expedite the process of getting these treatments to patients.

With access to patients established, how do you address scalability of this treatment in a field that's so customized?

While it might sound like a challenge to scale personalized medicine — it's a worthwhile challenge. Bock says that even though cell therapy is in its early stages still — the first treatment was approved by the FDA just five years ago — early studies have shown patients, who essentially have no other treatment options, can see life-saving results in as little as one treatment.

"We see in a large group of patients — 30 to 50 percent of patients — are cured with one dose," he says on the show.

CTMC has a 60,000-square-foot space two blocks away from MD Anderson. This critical lab space with 14 clean rooms was made available after its previous biotech tenant moved out. The setup can support up to 140 people, and the organization has grown to 80 people over the past few years.

Bock says CTMC is an engine for cell therapy research — one that can take a therapeutic from research to the clinic in about one to two years. Every year, he says CTMC can roll three to five therapeutics into the clinic phase.

And, Houston's an ideal place to do that.

"Houston has a chance to play a role in all aspects of cell therapy," he says, from discovery to the clinical side. "Some really interesting cell therapies that are in development were discovered here in Houston."

Bock shares more on how the impact CTMC is making on cell therapy advancement on the podcast. Listen to the interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.


Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

6 Houston startups disrupting industries with innovative technology

meet the finalists

Houston is no stranger to technology that's shaping the future. As the longtime location of NASA Johnson Space Center to home base for new ventures disrupting industries with their technology, the Bayou City has had its finger on the pulse of what's new and next for decades.

The Deep Tech Business category in our 2025 Houston Innovation Awards will honor an innovative startup providing technology solutions based on substantial scientific or engineering challenges, including those in the AI, robotics and space sectors.

Six deep tech companies have been named finalists for the 2025 award. They range from a company developing predictive software to accelerate the energy transition to a new venture that's developing humanoid robots.

Read more about these businesses, their founders and their breakthrough technologies below. Then join us at the Houston Innovation Awards on Nov. 13 at Greentown Labs, when the winner will be unveiled.

Tickets are now on sale for this exclusive event celebrating Houston Innovation.

ARIX Technologies

Industrial and robotics company ARIX Technologies is an integrated robotics and data analytics company that delivers inspection services. Its ARIX VENUS robot combines aerospace-grade engineering, advanced non-destructive testing (NDT) and AI-powered analytics to detect hidden corrosion under insulation for the downstream energy, petrochemical, and chemical processing sectors.

ARIX was founded in 2017 by Dianna Liu, a former ExxonMobil engineer. Craig Mallory serves as CEO. The company reports that it is scaling deployments with major Gulf Coast refineries, expanding its analytics platform to include predictive corrosion modeling and growing a global partner program.

Little Place Labs

Space tech company Little Place Labs is developing an AI, machine-learning software across a network of satellites that can provide insights from space in under seven minutes.

The company was founded in 2022 by CEO Bosco Lai and CTO Gaurav Bajaj. The company recently received an award from the U.S. Space Force that will support it in deploying multiple applications and products onto more than 55 satellites over the next 36 months for both national security and commercial use cases. The company won the Security, GovTech & Space competition at the SXSW Pitch showcase last year.

Newfound Materials

Newfound Materials has developed a predictive synthesis software platform for accelerating the discovery of novel materials for critical energy applications, such as batteries, magnets, catalysts, and more. It guides users on the best experiments to try in the lab to optimize the synthesis of their materials.

Newfound Materials was founded in 2024 by CEO Matthew McDermott and participated in the inaugural Activate cohort. The company plans to release a public web app soon. It also has plans to raise a pre-seed or angel round.

Paladin Drones

Paladian develops drone-as-first-responder (DFR) systems for public safety. Its technology gives first responders live aerial video before teams arrive, enabling quicker decisions, better resource allocation and reduced false alarms.

The company was founded in 2018 by Divyaditya Shrivastava and participated in the Y Combinator accelerator that year. The company raised a $5.2 million seed round in 2024 and another round for an undisclosed amount earlier this year. In the future, it plans to expand its DFR deployments into more cities, offer new payload delivery capabilities (like delivering Narcan and life vests), and enhance deconfliction features.

Persona AI

Persona AI is building modularized humanoid robots that aim to deliver continuous, round-the-clock productivity and skilled labor for "dull, dirty, dangerous, and declining" jobs.

The company was founded by Houston entrepreneur Nicolaus Radford, who serves as CEO, along with CTO Jerry Pratt and COO Jide Akinyode. It raised eight figures in pre-seed funding this year and also expanded its operations at the Ion. The company is developing its prototype of a robot-welder for Hyundai's shipbuilding division, which it plans to unveil in 2026.

Tempest Droneworx

Tempest Droneworx provides real-time intelligence collected through drones, robots and sensors. Its Harbinger software platform shares data through a video game engine and aims to provide teams with early warning and insight to help them make decisions faster.

The company was founded in 2021 by CEO Ty Audronis and COO Dana Abramovitz. It participated in the Mass Challenge Air Force Labs and won the Best Speed Pitch at SXSW earlier this year. The company is currently raising a $2.5M seed round.

---

The Houston Innovation Awards program is sponsored by Houston Community College, Houston Powder Coaters, FLIGHT by Yuengling, and more to be announced soon. For sponsorship opportunities, please contact sales@innovationmap.com.


Houston has the lowest inflation problem in the U.S., new study finds

Money Talk

Despite the national inflation rate sitting at 3 percent as of September 2025, the impact of inflation on Houston and the surrounding area isn't as severe as the rest of the U.S., a new study has revealed.

Houston-The Woodlands-Sugar Land ranked as the metro with the smallest inflation problem in the U.S. in WalletHub's October 2025 "Changes in Inflation by City" report.

The study tracked inflation changes for 23 major metropolitan statistical areas (MSAs) using Consumer Price Index data from the latest month available and compared to data from two months prior. The analysis also factored in inflation data from last year to analyze both short- and long-term inflation changes.

Compared to two months ago, the inflation rate in Houston fell by 0.1 percent, and local inflation is only 1.10 percent higher than it was a year ago, WalletHub said.

Houston residents may be feeling the sting a lot less than they did in January 2024, when WalletHub said the city had the 7th highest inflation rate in the country. And yet, Houstonians are increasingly concerned with the economy and its effects on inflation, a recent University of Houston survey found.

A separate WalletHub study named Texas the No. 1 most "financially distressed" state in the U.S. for 2025, adding to the severity of Texans' economical woes.

U.S. cities with the worst inflation problems

Denver-Aurora-Lakewood, Colorado topped the list as the city with the No. 1 worst inflation problem as of September. The Denver metro saw a 1 percent uptick in inflation when compared to two months prior, and it's 3.10 percent higher than it was a year ago.

Elsewhere in Texas, WalletHub ranked Dallas-Fort Worth-Arlington as the metro with the 8th lowest inflation problem nationwide. That's a fair shift from a previous report from June 2025 that ranked DFW the No. 1 U.S. metro with the lowest inflation issues.

The top 10 metros where inflation has risen the most as of September 2025 are:

  • No. 1 – Denver-Aurora-Lakewood, Colorado
  • No. 2 – Los Angeles-Long Beach-Anaheim, California
  • No. 3 – Chicago-Naperville-Elgin, Illinois-Indiana-Wisconsin
  • No. 4 – Boston-Cambridge-Newton, Massachusetts-New Hampshire
  • No. 5 –Minneapolis-St. Paul-Bloomington, Minnesota-Wisconsin
  • No. 6 – (tied) Philadelphia-Camden-Wilmington, Pennsylvania-New Jersey-Delaware-Maryland and Washington-Arlington-Alexandria, D.C.-Virginia-Maryland-West Virginia
  • No. 8 – Anchorage, Alaska
  • No. 9 – New York-Newark-Jersey City, New York-New Jersey-Pennsylvania
  • No. 10 – San Diego-Carlsbad, California
---

This article originally appeared on CultureMap.com.

Axiom Space taps solar array developer for first space station module

space contract

Houston-based Axiom Space is making progress on developing its commercial space station.

The company awarded Florida-based Redwire Corporation a contract to develop and deliver roll-out solar array (ROSA) wings to power the Axiom Payload Power Thermal Module (AxPPTM), which will be the first module for the new space station.

AxPPTM will initially attach to the International Space Station. AxPPTM will later separate from the ISS and rendezvous with Axiom’s Habitat 1 (AxH1) on orbit. Eventually, an airlock, Habitat 2 (AxH2) and finally the Research and Manufacturing Facility (AxRMF) will be added to the first two Axiom modules.

AxPPTM is anticipated to launch toward the end of 2027. The two-module station (AxPPTM and AxH1) is expected to be operational as a free-flying station by 2028, and the full four-module station around 2030.

The modules will be integrated and assembled at Axiom Space’s Assembly and Integration facility, making them the first human-rated spacecraft built in Houston.

Redwire’s ROSA technology was originally developed for the ISS, according to Space News. It has yielded a 100 percent success rate on on-orbit performance. The technology has also been used on NASA’s Double Asteroid Redirection Test mission, the Maxar-built Power and Propulsion Element for the Artemis Lunar Gateway and Thales Alenia Space’s Space Inspire satellites.

“As a market leader for space power solutions, Redwire is proud to be selected as a strategic supplier to deliver ROSAs for Axiom Space’s first space station module,” Mike Gold, Redwire president of civil and international space, said in a news release. “As NASA and industry take the next steps to build out commercial space stations to maintain U.S. leadership in low-Earth orbit, Redwire continues to be the partner of choice, enabling critical capabilities to ensure on-orbit success.”